These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 24681838)

  • 21. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study.
    Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
    Mod Rheumatol; 2014 Sep; 24(5):725-33. PubMed ID: 24372225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.
    Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Shoji T; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T
    Mod Rheumatol; 2014 Sep; 24(5):715-24. PubMed ID: 24313916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Certolizumab pegol and rheumatoid arthritis. Just another TNF alpha antagonist, no therapeutic advantage.
    Prescrire Int; 2010 Dec; 19(111):279. PubMed ID: 21355379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Certolizumab pegol (Cimzia) and ustekinumab (Stelara) for psoriatic arthritis.
    Med Lett Drugs Ther; 2014 Feb; 56(1435):10-2. PubMed ID: 24662976
    [No Abstract]   [Full Text] [Related]  

  • 25. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials.
    Bykerk VP; Cush J; Winthrop K; Calabrese L; Lortholary O; de Longueville M; van Vollenhoven R; Mariette X
    Ann Rheum Dis; 2015 Jan; 74(1):96-103. PubMed ID: 24092417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevation of KL-6 serum levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a report from the Japan College of Rheumatology Ad Hoc Committee for Safety of Biological DMARDs.
    Harigai M; Takamura A; Atsumi T; Dohi M; Hirata S; Kameda H; Nagasawa H; Seto Y; Koike T; Miyasaka N
    Mod Rheumatol; 2013 Mar; 23(2):284-96. PubMed ID: 22588312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial.
    Kivitz AJ; Schechtman J; Texter M; Fichtner A; de Longueville M; Chartash EK
    J Rheumatol; 2014 Apr; 41(4):648-57. PubMed ID: 24584918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Certolizumab for the treatment of refractory disseminated pyoderma gangrenosum associated with rheumatoid arthritis.
    Cinotti E; Labeille B; Perrot JL; Pallot-Prades B; Cambazard F
    Clin Exp Dermatol; 2014 Aug; 39(6):750-1. PubMed ID: 24984791
    [No Abstract]   [Full Text] [Related]  

  • 29. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
    Williams VL; Cohen PR
    Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adalimumab-induced acute interstitial lung disease in a patient with rheumatoid arthritis.
    Dias OM; Pereira DA; Baldi BG; Costa AN; Athanazio RA; Kairalla RA; Carvalho CR
    J Bras Pneumol; 2014; 40(1):77-81. PubMed ID: 24626274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interstitial pneumonitis associated with infliximab therapy.
    Villeneuve E; St-Pierre A; Haraoui B
    J Rheumatol; 2006 Jun; 33(6):1189-93. PubMed ID: 16622902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Further evidence for influenza and pneumococcal vaccination in patients treated with disease modifying antirheumatic drugs and anti-tumor necrosis factor agents.
    Kapetanovic MC
    J Rheumatol; 2014 Apr; 41(4):626-8. PubMed ID: 24692602
    [No Abstract]   [Full Text] [Related]  

  • 33. Disseminated superficial porokeratosis.
    Brauer JA; Mandal R; Walters R; Solomon G; Kundu RV; Strober BE
    Dermatol Online J; 2010 Nov; 16(11):20. PubMed ID: 21163171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential use of TNF-α inhibitors in systemic sclerosis.
    Murdaca G; Spanò F; Contatore M; Guastalla A; Puppo F
    Immunotherapy; 2014; 6(3):283-9. PubMed ID: 24762073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis.
    Ramiro S; van Tubergen AM; Landewé RB
    Expert Rev Clin Immunol; 2010 Sep; 6(5):713-20. PubMed ID: 20828279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study.
    Akiyama M; Kaneko Y; Yamaoka K; Kondo H; Takeuchi T
    Rheumatol Int; 2016 Jun; 36(6):881-9. PubMed ID: 27072347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe fungal infections linked to drugs.
    Kuehn BM
    JAMA; 2008 Oct; 300(14):1639. PubMed ID: 18840827
    [No Abstract]   [Full Text] [Related]  

  • 39. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review.
    Hadjinicolaou AV; Nisar MK; Bhagat S; Parfrey H; Chilvers ER; Ostör AJ
    Rheumatology (Oxford); 2011 Dec; 50(12):2297-305. PubMed ID: 22019799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of extraintestinal solid cancer with anti-TNF therapy in adults with inflammatory bowel disease: review of the literature.
    Hudesman D; Lichtiger S; Sands B
    Inflamm Bowel Dis; 2013 Mar; 19(3):644-9. PubMed ID: 23314243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.